【全新发售】Cellectra CD14纳米分选磁珠：高效分选，精准捕获

单核细胞作为免疫系统的核心成员，不仅是炎症调控、病原防御的关键执行者，更是巨噬细胞与树突状细胞的前体细胞，在肿瘤免疫、细胞治疗（如CAR-M疗法）和树突细胞疫苗研发中具有不可替代的作用。然而，无论是基础研究还是临床转化，高效获取高纯度、高活性的单核细胞及其衍生细胞始终是首要挑战。CD14作为单核细胞、巨噬细胞和树突细胞的经典表面标志物，是分选目标细胞的理想靶点。

ACROBiosystems百普赛斯依托自主研发的“新一代磁珠技术开发平台“，重磅推出的新品：Cellectra CD14纳米分选磁珠（货号：MBS-S001），专为CD14⁺细胞的分离纯化而设计。产品通过在磁珠表面偶联高亲和力的抗CD14单克隆抗体，可实现对单核细胞与巨噬细胞的高效识别与靶向捕获。

Cellectra CD14纳米分选磁珠核心优势：

• 高细胞分选纯度

The CD14+ cells were isolated from human PBMCs using Cellectra Human CD14 nBeads, premium grade (for cells）(ACROBiosystems, Cat. No. MBS-S001). The isolated cells and non-isolated cells were respectively stained using PE anti-human CD14 antibody, and then analyzed by FCS Express 7 software.

The sorting effect of PBMCs from different donors was slightly different, but all of them could guarantee good purity and cell recovery.

• 高稳定性

The Cellectra Human CD14 nBeads, premium grade (for cells）(ACROBiosystems, Cat. No. MBS-S001) after acceleration 0-21 days at 37℃or freeze & thaw three times still have good isolation efficiency.

ACROBiosystems百普赛斯全新推出新一代磁珠技术开发平台，旨在为细胞治疗工艺开发提供系统化、标准化的磁珠解决方案。平台基于先进的蛋白偶联工艺，构建了涵盖ActiveMax® 细胞激活、Cellectra细胞分选等功能模块的产品体系，提供微米级与纳米级等多种粒径规格，以全面满足细胞制备的多样化需求。

核心磁珠原材料与关键技术均由ACROBiosystems百普赛斯自主研发与生产开发，实现全链条可控，为产品的质量稳定性与供应安全提供坚实保障，同时依托成熟的工艺设计与严格的质量控制体系，确保产品具备优异性能与高批间一致性。并支持定制化服务，包括特定靶点磁珠开发与GMP版本升级等，满足从基础研究到商业化生产的全流程应用场景。

该平台的推出，标志着ACROBiosystems在细胞治疗关键原材料领域的又一重要布局，将与我司GMP细胞因子、无血清培养基、质控试剂盒等产品线协同，持续为全球行业客户提供高质量、可拓展的Next Generation解决方案，助力细胞治疗从实验室走向临床与产业化落地。

Activation of the purified human T Cells. The purified human T cells were activated using Human T cell Activation/Expansion CD3/CD28 Beads, (ACRO, Cat. No. GMP-MBS001) and Competitor-Beads respectively for 24 hours with CTS Optimizer Medium. Cells were fluorescently stained using PE labeled anti-human CD25 antibody and labeled FITC anti-human CD69 antibody and analyzed by flow cytometry.

点击查看更多数据

ActiveMax® Human CD19 μBeads, premium grade (for cells) (Cat. No. MBS-C002) can activate CD19-specific CAR-T cells by detecting the secretion of IFN- γ in vitro (Routinely tested).